A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma

Inclusion Criteria:

- The participant may have no more than 2 prior lines of systemic therapies (neoadjuvant
and adjuvant therapies will not be considered as a prior line of therapy) for advanced
or metastatic disease and is suitable to receive gemcitabine and docetaxel therapy.
All previous therapies must have completed ≥ 3 weeks (21 days) prior to first dose of
study drug.

- In the Phase 2 part, prior olaratumab/doxorubicin combination therapy in 1 prior
treatment line is allowed.

- Prior olaratumab therapy must have been received with doxorubicin as indicated on
the olaratumab label.

- Prior olaratumab therapy must have included at least 2 full cycles of
olaratumab/doxorubicin (that is, a minimum of 4 doses of olaratumab).

- Participants, who completed at least 2 cycles of combination
olaratumab/doxorubicin therapy then discontinued doxorubicin due to toxicity or
maximum dosing and proceeded to olaratumab monotherapy, are eligible.

- The most recent dose of olaratumab must have been received within 180 days of
randomization in this study.

- Availability of tumor tissue is mandatory for study eligibility. The participant must
have consented to provide archived formalin-fixed paraffin-embedded tumor tissue or be
subject to a pre-treatment re-biopsy of primary or metastatic tumor tissue for future
central pathology review and translational research (if archived tissue is
unavailable).

- The participant has adequate hematologic, organ, and coagulation function within 2
weeks (14 days) prior to enrollment (Phase 1b) or randomization (Phase 2).

Exclusion Criteria:

- The participant is diagnosed with gastrointestinal stromal tumor (GIST) or Kaposi
sarcoma.

- The participant has active central nervous system (CNS) or leptomeningeal metastasis
(brain metastasis) at the time of enrollment (Phase 1b) or randomization (Phase 2).
Participants with a history of a CNS metastasis previously treated with curative
intent (for example, stereotactic radiation or surgery) that have not progressed on
follow-up imaging, have been asymptomatic for at least 60 days, and are not receiving
systemic corticosteroids and or/anticonvulsants, are eligible. Participants with signs
or symptoms of neurological compromise should have appropriate radiographic imaging
performed before enrollment (Phase 1b) /randomization (Phase 2) to rule out brain
metastasis.

- The participant has received prior treatment with gemcitabine or docetaxel. Note:
Participants previously enrolled in the I5B-MC-JGDJ (NCT02451943) or any other blinded
study with olaratumab are not eligible to participate in this trial.

- The participant has electively planned or will require major surgery during the course
of the study.

- Females who are pregnant or breastfeeding.

- The participant has an active fungal, bacterial, and/or known viral infection
including human immunodeficiency virus (HIV) or viral (A, B, or C) hepatitis
(screening is not required).